Furthermore, additional adjuvant treatment can be considered in patients with residual disease, particularly in those with human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer [6,7,8,9]. Here, ERBB2 is linked to triple-negative breast carcinoma.